cefdinir and Rhinitis

cefdinir has been researched along with Rhinitis* in 2 studies

Other Studies

2 other study(ies) available for cefdinir and Rhinitis

Article	Year
Balancing the benefits and risks of empirical antibiotics for sinusitis: a teachable moment. JAMA internal medicine, 2014, Volume: 174, Issue:8 Topics: Acute Disease; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cefdinir; Cephalosporins; Enterocolitis, Pseudomembranous; Fatal Outcome; Humans; Immunocompromised Host; Infliximab; Male; Rhinitis; Risk Assessment; Sinusitis	2014
Management update of acute bacterial rhinosinusitis and the use of cefdinir. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2002, Volume: 127, Issue:6 Suppl The pathogenesis, bacteriology, diagnosis, and antimicrobial treatment of acute bacterial rhinosinusitis (ABRS) is reviewed. Most cases of ABRS arise as complications of the rhinosinusitis of colds and other acute viral respiratory infections. Nose blowing during colds may be a risk factor for ABRS by propelling bacteria-laden nasal fluid into the sinus cavity. The bacterial causes of ABRS continue to be S pneumoniae. H influenzae, other streptococcal species, M catarrhalis, anaerobes, and S aureus. Clinical diagnosis of ABRS is based on obtaining a history of a cold or influenza-like illness that is no better or worse after >/=7 days. A 10-day course of treatment with an antimicrobial effective against resistant S pneumoniae and H influenzae is recommended. A clinical trial was reviewed in which cefdinir was effective in treating ABRS. Topics: Acute Disease; Anti-Bacterial Agents; Bacterial Infections; Cefdinir; Cephalosporins; Humans; Rhinitis; Sinusitis	2002

Article

Year

Balancing the benefits and risks of empirical antibiotics for sinusitis: a teachable moment.

JAMA internal medicine, 2014, Volume: 174, Issue:8

Topics: Acute Disease; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Cefdinir; Cephalosporins; Enterocolitis, Pseudomembranous; Fatal Outcome; Humans; Immunocompromised Host; Infliximab; Male; Rhinitis; Risk Assessment; Sinusitis

2014

Management update of acute bacterial rhinosinusitis and the use of cefdinir.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2002, Volume: 127, Issue:6 Suppl

The pathogenesis, bacteriology, diagnosis, and antimicrobial treatment of acute bacterial rhinosinusitis (ABRS) is reviewed. Most cases of ABRS arise as complications of the rhinosinusitis of colds and other acute viral respiratory infections. Nose blowing during colds may be a risk factor for ABRS by propelling bacteria-laden nasal fluid into the sinus cavity. The bacterial causes of ABRS continue to be S pneumoniae. H influenzae, other streptococcal species, M catarrhalis, anaerobes, and S aureus. Clinical diagnosis of ABRS is based on obtaining a history of a cold or influenza-like illness that is no better or worse after >/=7 days. A 10-day course of treatment with an antimicrobial effective against resistant S pneumoniae and H influenzae is recommended. A clinical trial was reviewed in which cefdinir was effective in treating ABRS.

Topics: Acute Disease; Anti-Bacterial Agents; Bacterial Infections; Cefdinir; Cephalosporins; Humans; Rhinitis; Sinusitis

2002